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Abstract 87 
BACKGROUND: Despite smoking being a well-established risk factor for pancreatic cancer (PC), there is a 88 
need to further characterize PC risk according to lifespan smoking patterns and other smoking features 89 
such as tobacco type. Our aim was to deeply investigate them within a large European case-control study. 90 
METHODS: Tobacco smoking habits and other relevant information was obtained from 2,009 cases and 91 
1,532 controls recruited in the PanGenEU study using standardized tools. Multivariate logistic regression 92 
analysis was performed to evaluate PC risk by smoking characteristics and interactions with other PC risk 93 
factors. Fractional polynomials and restricted cubic splines were used to test for non-linearity of the dose-94 
response relationships and to analyse their shape.  95 
RESULTS: Relative to never-smokers, current smokers (OR=1.72, 95%CI: 1.39-2.12), those inhaling into 96 
the throat (OR=1.48, 95%CI: 1.11-1.99), chest (OR=1.33, 95%CI: 1.12-1.58), or using non-filtered 97 
cigarettes (OR=1.69, 95%CI: 1.10-2.61), were all at an increased PC risk. PC risk was highest in current 98 
black tobacco smokers (OR=2.09, 95%CI: 1.31-3.41), followed by blond tobacco smokers (OR=1.43, 99 
95%CI: 1.01-2.04). Childhood exposure to tobacco smoke relative to parental smoking was also associated 100 
with increased PC risk (OR=1.24, 95%CI: 1.03-1.49). Dose-response relationships for smoking duration, 101 
intensity, cumulative dose, and smoking cessation were non-linear and showed different shapes by 102 
tobacco type. Effect modification by family history of PC and diabetes was likely.  103 
CONCLUSIONS: This study reveals differences in PC risk by tobacco type and other habit characteristics, 104 
as well as non-linear risk associations. 105 




  110 
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Introduction 111 
Pancreatic cancer (PC) is one of the deadliest cancer types worldwide (5-year relative survival rate 112 
in the range 5-15%) (1). Disastrously, estimates of PC incidence are increasing both in USA and Europe 113 
(2). Despite the aetiology of PC is relatively unknown, it is estimated that 10-30% of all PC cases are 114 
caused by smoking (3). Prevention of smoking is therefore a strong measure to reduce the burden of PC in 115 
the population. 116 
While the association between smoking and PC is well-established, a detailed characterization of 117 
tobacco smoking habits in relation to PC risk is still lacking. A meta-analysis including 10,490 cases and 118 
526,813 controls, showed that being a current smoker, jointly with a longer smoking duration and a higher 119 
smoking intensity, were associated with an increase in PC risk (4). However, the authors assumed a linear 120 
trend for PC risk associated with increasing smoking exposure, a fact that was disputed by Zou et al. in an 121 
updated analysis combining 9,044 cases and 32,039 controls that showed a non-linear dose-response 122 
relationship between several smoking characteristics and PC risk (5). In addition, the pooled analysis within 123 
the Pancreatic Cancer Case-Control Consortium (PanC4), including 6,507 cases and 12,890 controls, 124 
indicated that after a certain amount of smoking exposure PC risk levelled-off (6), shedding a different 125 
perspective on the dose-response relationship of smoking in relation to PC risk. However, in the 126 
aforementioned studies, an exploration of the shape of the association between smoking measures and 127 
PC risk was not further pursued. The shape of the dose-response relationship between cigarette smoking 128 
and PC risk was investigated in a recent meta-analysis of 38 case-control and 40 cohort studies (7). Risk 129 
patterns of PC in current versus smokers were compared in this study for smoking intensity and duration, 130 
ignoring the contribution to risk of former smokers. To understand multi-dimensional aspects of smoking in 131 
PC aetiology, there is a need to provide consistent risk estimates for all smoking groups and to address the 132 
mutual influence of smoking intensity and duration. 133 
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Moreover, several aspects of tobacco smoking habits have not been considered until now. For 134 
instance, differences in PC risk by either black or blond tobacco use have not been explored despite the 135 
presumed differences in their chemical composition and damaging effects (8,9). In fact, several studies 136 
have shown that black tobacco is associated with higher risk of bladder (8), colorectal (10), oesophageal 137 
(11), and head-and-neck cancer (12,13), than blond tobacco.  138 
Therefore, we set out to investigate the association and dose-response relationship between 139 
tobacco smoking and PC risk in a large European population, considering every aspect of the smoking 140 
habit including use of black versus blond tobacco.  141 
 142 
Methods 143 
Study design and participants 144 
The PanGenEU is an ongoing multicentre case-control study initiated in 2007, recruiting 145 
participants from six European countries (Germany, Ireland, Italy, Spain, Sweden and United Kingdom) 146 
across 28 centres. Newly diagnosed PC patients >18 years old and controls matched by age (±10 years), 147 
gender, and geographical area were included if they had lived in the study area for at least 6 months. A 148 
rapid ascertainment approach was applied: PC cases with a suspicion of the disease were recruited and 149 
remained in the study if the diagnosis was verified by the treating physician. Controls, sex-, age-, and 150 
centre- individually matched to cases, were mostly hospital-based and eligible if principal diagnosis at 151 
admission was unrelated to known risk factors of PC. Conditions of admission of controls are reported in 152 
Supplementary Methods. Population-based controls (Sweden and Ireland) were eligible if history of PC 153 
was absent. Participation rates were 86.3% for cases and 77.8% for controls. The study was approved by 154 
the IRB of all participant centres and all subjects gave written informed consent. More details of the study 155 
are provided elsewhere (14,15). 156 
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Variables 157 
Personal interviews to the study subjects were conducted by trained monitors using standardized 158 
protocols and questionnaires to obtain detailed information on lifetime smoking habits, among other PC risk 159 
factors. The smoking status of the participants was categorized into never-smokers if they smoked <100 160 
cigarettes during their lifetime; occasional smokers if they smoked ≥1 cigarette/day for ≥6 months; former 161 
smokers if they quitted smoking for >1 year; and current smokers otherwise (>100 cigarettes during lifetime 162 
without permanent smoking cessation). Information on smoking habits by tobacco type (only black, blond 163 
or both) was only collected in the Spanish centres. Smoking exposure was further assessed by the age at 164 
smoking initiation (years), age when last smoked (years), cigarettes/cigar/pipe-use (yes, no), the amount of 165 
cigarettes/cigars/pipes smoked in units of time (days, months, years), depth of inhalation (mouth, throat, 166 
chest), filter-use (filtered cigarettes, non-filtered, both), and smoking status of the parents (never- or ever-167 
smoker). From these characteristics, data on smoking duration (years), smoking intensity for cigarettes (per 168 
day) and cigars/pipes (per week), and time since cessation (years) was derived. Number of pack-years, 169 
representing cumulative dose, was calculated as (cigarettes per day/20)*smoking duration in years. 170 
Smoking variables by use of tobacco type were generated likewise. Environmental tobacco smoke (ETS) 171 
exposure during childhood was categorized according to the smoking status of the parents (none, one or 172 
both).  173 
Statistical analysis 174 
Imputation of missing values, assumed to be at random, was performed using the Random Forest 175 
algorithm (R package missForest). Predictor variables such as centre, country, and case-control status 176 
were kept in the imputation set. The performance of the imputation (Supplementary Table 1) was assessed 177 
by calculating the out of bag mean square error (OOB), representing the mean of squared differences 178 
between each observed value and its prediction, based on random forest trees (n=100 was applied). The 179 
average OOB for all smoking variables was 5.27, with categorical variables presenting a markedly lower 180 
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estimate (OOB=0.04), indicating a better imputation performance of the latter. Use of unimputed data of all 181 
continuous variables, for which the proportion of missing values was relatively low (6.7%), was therefore 182 
deemed more appropriate for dose-response analyses. The performance of the imputation was also 183 
assessed with concordance rates between the observed and imputed data, considering a test dataset 184 
consisting of only subjects with complete data and missing values introduced by following the missingness 185 
rates of the original data. The concordance of all categorical variables was 94.4%.  186 
Differences between cases and controls regarding smoking characteristics were evaluated by χ2 187 
and Student’s t-test (or Kruskal–Wallis test, where appropriate). Unconditional logistic regression analysis 188 
was performed to estimate odds ratios (OR) and 95% Confidence Intervals (95%CI). Never-smokers were 189 
chosen as the reference category, except for the variables “age when last smoked” and “time since 190 
smoking cessation”, where current smokers were taken as the reference. Tertiles were created for the 191 
continuous variables based on the distribution of controls. A p-value for trend was calculated by assuming 192 
ordinal variables in linear regression models. Age (≤54, 55-64, 65-74, ≥75 years), gender and country-193 
adjusted models (aOR) were considered (Model 1). For the tobacco type-specific analyses within the 194 
Spanish PanGenEU study population, the same model was applied, but replacing country by region (East, 195 
Central and Northern Spain). The attributable risk (AR) of smoking in relation to PC (population exposed: 196 
59%) was calculated from the fitted multivariate adjusted logistic regression models (R packages attribrisk 197 
and epiR). Since heterogeneity by country (p<0.05) was evident for all smoking variables (for example, p-198 
value for interaction by smoking status=0.007: Supplementary Figure 1), random effects for country were 199 
applied in mixed effects models. Due to absence of heterogeneity in the Spanish study population, logistic 200 
regression models without random effects were considered.  201 
The influence of confounding factors or effect modification on the association was assessed for 202 
several variables: gender (female, male), age (<65 years, ≥ 65 years), obesity (body mass index >30: yes, 203 
no), diabetes (no, yes less than 2 years, yes more than 2 years), asthma (yes, no), chronic pancreatitis 204 
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(yes, no), alcohol status/consumption (never, former, current), presence of periodontitis (yes, no) and 205 
recession (yes, no), educational level as a proxy for socioeconomic status (low, medium, high), and family 206 
history of PC (yes, no).  Variables changing estimates by more than 10% or having a significant influence 207 
in the model (diabetes and family history of PC in some smoking-related variables) were considered as 208 
potential confounders. The le Cessie-van Houwelingen-Copas-Hosmer unweighted sum of squares test 209 
indicated a high goodness of fit of the models (16). Effect modification was assessed in interaction and 210 
stratified analyses. Additive interaction by time-related variables such as smoking duration was also 211 
evaluated by the relative excess risk due to interaction (RERI) and Delta-method Cis (17,18).  212 
To test for interaction, a likelihood ratio (LR) test was performed comparing models with and 213 
without an interaction term between the smoking variables and the covariates (e.g., age, gender, BMI and 214 
obesity, diabetes, asthma, alcohol, periodontitis, recession, educational level, and family history of PC). 215 
Effect modification was tested further via stratified analyses. To assess interaction by time-related variables 216 
we explored the combined effect of smoking duration and other smoking characteristics such as tobacco 217 
type on PC risk. Smoking duration was categorized into <20, 20-30, and ≥30 years of smoking and 218 
stratified further by tobacco type considering never-smokers as the reference category. 219 
To assess the dose-response relationships, PC risk estimates were calculated per 1-unit of 220 
increase in continuous smoking exposure variables considering linear and non-linear models if so indicated 221 
by fractional polynomials (R package mfp) (19). In addition, restricted cubic splines were used to confirm 222 
non-linear associations and for modelling the shape of the dose-response relationships (R package 223 
splines)(20). Non-linearity of the models was tested via the likelihood-ratio test comparing the model with 224 
and without restricted cubic splines. Knots were set at the 10%, 50% and 90% percentile of the exposure 225 
distribution, as comparable results were obtained with five knots (21).  226 
Sensitivity analyses were performed comparing the risk estimates in magnitude and trend 227 
regarding the unimputed and imputed data, and the PanGenEU study population with and without Italy 228 
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(since Italy provided cases only). As information bias could be induced by neglecting the quantity of 229 
smoking exposure, adjustment for cumulative dose (pack-years) was considered, thereby accounting for 230 
both smoking duration and smoking intensity. Additional adjustments were made also for smoking intensity 231 
and duration separately, to assess both the individual and joined effects of smoking characteristics 232 
independent of smoking duration and/or intensity. These adjustment variables were considered on the 233 
continuous scale and modelled as fractional polynomials to account for non-linear effects. To further 234 
assess the performance of the restricted cubic splines, additional smoothing was applied by varying the 235 
degrees of freedom, allowing more flexibility into the model (22).  236 
The threshold for statistical significance in two-sided tests was set at p-value<0.05. Data was 237 
analysed with R-project (version 3.4.1) (23).  238 
 239 
Results 240 
Table 1 shows the characteristics of the 2,009 cases and 1,532 controls included in this analysis. 241 
The Spanish centres contributed the most to both cases (N=876) and controls (N=762). PC cases 242 
presented more frequently with a family history of PC and a diagnosis of diabetes or chronic pancreatitis. 243 
Table 2 shows PC risk associated with smoking characteristics. The prevalence of smoking was 244 
higher in cases (27.4%) than in controls (17.6%), with a corresponding aOR of 1.72 (95%CI: 1.39-2.12) for 245 
current smokers compared to never-smokers. Furthermore, a statistically significant increased trend (p-246 
value<0.001) in PC risk was observed for longer smoking duration, higher smoking intensity and higher 247 
cumulative dose. The use of non-filtered cigarettes increased risk of PC more prominently (aOR=1.69, 248 
95%CI: 1.10-2.61), although use of filtered cigarettes was also associated with an increased PC risk 249 
(aOR=1.25, 95%CI: 1.06-1.48). Marked increases in PC risk were also observed for inhalation into the 250 
throat (aOR=1.48, 95%CI: 1.11-1.99) and chest (aOR=1.33, 95%CI: 1.12-1.58). Childhood exposure to 251 
ETS by smoking parents (vs. non-parental exposure) was also associated with a 24% (95%CI: 1.03-1.49) 252 
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increased PC risk. Risk for former smokers decreased progressively with longer time since smoking 253 
cessation when compared to current smokers (aOR for 14-28 years after cessation=0.67, 95%CI: 0.51-254 
0.88). A negative trend of the risk was also observed if compared to never-smokers (PC risk was 255 
diminished from 14 years of cessation), and when considering smoking cessation time at 5-year intervals 256 
(Supplementary Table 2). No significant associations between PC risk and pipe/cigar-use or other smoking 257 
variables were observed (Supplementary Table 3). Additional adjustment for diabetes and family history of 258 
PC led to minimal differences in risk estimates (Supplementary Table 3). Effect modification was apparent 259 
only for family history of PC and diabetes status (Supplementary Table 4), pointing towards a higher PC 260 
risk among current smokers with family history of the disease (aOR=2.24, 95%CI: 0.66-7.61) and former 261 
smokers with diabetes (aOR=1.44, 95%CI: 0.91-2.28) (p-value for interaction<0.001). 262 
Table 3 shows PC risk estimates by tobacco type in PanGenEU-Spain. Compared to never-263 
smokers, PC risk was significantly increased for smokers of only black tobacco (aOR=1.55, 95%CI: 1.13-264 
2.12) and of both tobacco types (aOR=1.58, 95%CI: 1.14-2.17). Considering smokers of only blond 265 
tobacco, PC risk tended to be increased (aOR=1.23, 95%CI: 0.94-1.62), though without reaching statistical 266 
significance. When further stratifying by smoking status, a significant increase in risk was observed for 267 
current smokers of only black tobacco (aOR=2.09, 95%CI 1.31 - 3.41) and blond tobacco (aOR=1.43, 95% 268 
CI: 1.01-2.04). Former smokers of only black tobacco were at increased, though milder, PC risk 269 
(aOR=1.40, 95%CI: 0.98-1.99).  270 
Table 4 shows the combined effect of smoking duration and type of tobacco on PC risk. Compared 271 
to never-smokers, smoking for ≥30 years of both tobacco types was associated with a higher PC risk than 272 
smoking only black or blond tobacco (aOR=2.05, 95%CI: 1.25-3.36; RERI=0.206, 95%CI: -0.49-0.91).  273 
Table 5 shows risk estimates for continuous smoking variables associated with PC. Non-linear 274 
associations were evident for smoking duration and intensity, cumulative dose, time since cessation and 275 
age at smoking initiation. Adjusted fractional polynomials models suggested a statistically significantly 276 
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higher PC risk per 1-unit increase in smoking duration, smoking intensity and cumulative dose, and 277 
decreasing PC risks for age at smoking initiation and time since smoking cessation. Linear associations 278 
were observed for other variables such as intensity of smoking cigars/pipes (data not shown). The 279 
restricted cubic splines approximating the shape of the dose-response relationships confirmed these non-280 
linear associations. Compared to never-smokers, smoking for >25 years (Figure 1, A-B) and smoking >20 281 
cigarettes/day (Figure 1, D-E) was associated with a statistically significant increase of PC risk. Similarly, a 282 
cumulative dose of >14 pack-years was associated with increased PC risk (Figure 1, C). Visual inspection 283 
for smoking intensity and cumulative dose was suggestive of plateauing of PC risk, at approximately 27 284 
cigarettes/day or pack-years. Concerning time since smoking cessation (Figure 1, F-I), and relative to 285 
current smokers, risk appeared to decrease between 8 and 11 years of cessation and after around 18 286 
years of cessation regardless of cumulative dose. In between these periods, the significant effect 287 
disappeared. By tobacco type, corresponding periods of significant decrease in PC risk were observed for 288 
black tobacco (after about 14 years since cessation) and for blond tobacco (between 2 and 8 years and 289 
after >20 years of cessation).  290 
No relevant differences in the trend or magnitude of the estimates were found in sensitivity 291 
analyses (Supplementary Tables 3, 5,to 7), including further smoothing of the splines fit (Supplementary 292 
Figure 2). In analyses adjusting for smoking intensity, risk estimates decreased in magnitude but showed a 293 
similar trend. By tobacco type, this adjustment did not affect either the associations nor the shapes of the 294 
relationships despite black tobacco smokers smoked heavier and for a longer time (Supplementary Table 295 
8). Importantly, adjustment for smoking duration led to statistically non-significant risk estimates and 296 
change in the shape of the dose-response relationships (Supplementary Table 9). Joint effect analyses of 297 
smoking intensity and duration showed that long-lasting smoking together with intense smoking increase 298 
pancreatic cancer risk, whereas for less intense smoking the association weakened (Supplementary Table 299 
10).  300 
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 301 
Discussion 302 
The present study confirms that, in comparison to never-smokers, being a current smoker 303 
increases the risk of PC by 72%. In terms of attributable risk, this study also endorses that around 16% 304 
(95%CI: 9.24-22.47) of all PC diagnoses could be avoided through tobacco preventive measures. A more 305 
detailed examination of smoking characteristics showed that the use of non-filtered cigarettes, deep 306 
inhalation into the throat or chest, and exposure to tobacco smoke in the parental household were all 307 
associated with increased PC risk. PC risk in black tobacco smokers was significantly higher compared to 308 
never-smokers, with blond tobacco smokers showing a less prominent risk pattern. Analysis of dose-309 
response relationships corraborated that a higher smoking intensity, longer smoking duration, and 310 
increased levels of cumulative dose were associated further with an increased PC risk, whereas smoking 311 
cessation led to a gradual decline in PC risk, all in a non-linear manner. 312 
Our results are concordant with earlier studies on the same topic. Regarding the magnitude of PC 313 
risk associated with current versus never tobacco smoking, a meta-analysis and pooled analyses from the 314 
PanC4 and the Pancreatic Cancer Cohort Consortium showed similar estimates (RR=1.74, 95%CI: 1.61-315 
1.87, OR=2.20, 95%CI: 1.71-2.83 and OR=1.77, 95%CI: 1.38-2.26, respectively) (4,6,24). Similarly, our 316 
study confirmed the trends and timing of tobacco smoking (4,6), the excess risk conferred by tobacco 317 
smoking (4,25,26), the non-linear tobacco-PC associations (5,7), and risk due to childhood ETS (27). 318 
Compared with studies restricting ETS exposure to never-smokers, we also did not observe significant risk 319 
estimates (aOR=1.24, 95%CI: 0.95-1.63) (28,29), suggesting that smokers, possibly more likely being 320 
exposed to childhood ETS, were driving this association in the overall analyses (aOR for current smokers 321 
exposed to parental smoking vs never smoking exposure =2.01; 95%CI: 1.50-2.69). In contrast to the 322 
positive association between current cigar/pipe smokers and PC risk reported before (4,30), we did not 323 
observe a significant associations in our study, probably due to low statistical power. 324 
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 325 
Effect-modification factors 326 
The higher PC risk among smokers with family history of PC was previously described in our study 327 
population (14). Although statistical significance was not reached, former smoking diabetes patients tended 328 
to have a higher PC risk too. Were this true, lifestyle changes among diabetic patients including smoking 329 
cessation, which in turn may lead to weight gain and insulin resistance (31),(32), might explain this finding. 330 
Previous studies suggested differences in smoking effects on PC risk by gender (5,6), although they failed 331 
to demonstrate effect modification by this variable. Similarly, non-significant differences by gender were 332 
found in our study, which included a large female sample with a relatively high smoking prevalence.  333 
Dose-response relationships 334 
Non-linear relationships of the association between smoking variables and PC risk were supported 335 
by both fractional polynomials and restricted cubic splines approaches. Since fractional polynomials in 336 
regression models become imprecise with small sample sizes (22), we based the dose-response curves on 337 
results derived from restricted cubic splines, which allow a more flexible modelling (33). Concordant with 338 
the observation of non-linear associations for smoking duration, intensity, and cumulative dose, a plateuing 339 
in the dose-response relationship was apparent. This observed pattern was previously reported (5,7), and 340 
could be attributed to the saturation of the detoxification processes of tobacco carcinogens in the body 341 
(34), or to a presumably weaker inhalation of tobacco smoke but stronger DNA repair efficiency among 342 
heavy smokers (35,36), amongst other factors. Non-linear associations for smoking cessation, with  343 
decreased PC risk after 20 years of smoking cessation, were also suggested (5) and confirmed by other 344 
studies (7). However, in these earlier studies, consideration was not given to the influence of smoking 345 
intensity and duration on these associations. Patterns in PC risk in our study changed after adjusting for 346 
smoking duration mainly, whereby the magnitude of the risk estimates was affected (Supplementary Table 347 
9).  348 
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Black versus blond tobacco-use  349 
Compared to never-smokers, black tobacco smokers showed a significantly higher PC risk, this 350 
tobacco type appearing to be more harmful than blond tobacco. This result is consistent with the few 351 
studies that examined the association between smoking by tobacco type in bladder (8,37,38) and other 352 
cancers (10–13). Smoking both black and blond tobacco for a long time (≥30 years) tended to be related to 353 
higher PC risk, this also being shown in previous studies on tobacco smoking and bladder cancer (8).  354 
The difference between the two tobacco types could be explained by their smoke composition: 355 
black tobacco mostly contains early-stage carcinogens, such as N-nitrosamines and aromatic amines 356 
including 4-amino-biphenyl and 2-naphthylamine (39), whereas blond tobacco may mostly consist of late-357 
stage carcinogens (37). It is conceivable that the two tobacco types contribute to pancreas carcinogenesis 358 
through different mechanisms: black tobacco may predominantly cause DNA mutations whereas blond 359 
tobacco may preferentially act through epigenetic change, as has been shown for LINE-1 (9). As a 360 
consequence, an immediate and significantly higher increase in PC risk could be expected in black tobacco 361 
smokers, while blond tobacco might need a longer time to trigger PC development. This may also imply 362 
that following smoking cessation of blond tobacco PC risk can keep increasing for some time, slowing 363 
down after recovery of certain DNA methylation changes. In fact, methylation changes due to smoking 364 
seem to persist up to 22 years after smoking cessation (40). For black tobacco, instead, the PC risk 365 
reduction effects might not take place or might require longer since smoking cessation. Our results support 366 
these hypotheses to some extent. Compared to never-smokers, not only did black tobacco smoking have a 367 
more detrimental effect on PC risk, but also the risk tended to increase soon after smoking initiation, 368 
whereas downward risks were observed after smoking cessation for >10 years. A similar decreasing risk 369 
with long-term smoking cessation of black tobacco has been observed in bladder cancer in some (37,38), 370 
but not all (8), studies. Among blond tobacco smokers, the trend towards a reduction in PC risk became 371 
evident shortly after smoking cessation (Supplementary Table 9). The shape of dose-response curves 372 
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supported the aforementioned trends, specifically regarding smoking cessation. Thus, our study suggests 373 
that black tobacco consumption may play a role in several steps of the carcinogenic process with possibly 374 
both early and late-stage carcinogens being involved. For blond tobacco, our results point to a two-tier 375 
mechanism after smoking cessation driven by late-stage carcinogens, the first consisting of a sudden 376 
change in risk estimates with risk levels more akin to never-smokers likely due to desaturation of 377 
detoxification routes of tobacco-carcinogens (5,41), the second showing risks levelling-off after 378 
approximately 20 years of smoking cessation, once alteration of DNA methylation levels of key genes 379 
regain the state of normalcy. 380 
Among the limitations of the study, stratifying by tobacco type might have underpowered the 381 
analyses to detect any differences. As in any other study, subgroup analyses and multiple statistical tests 382 
are prone to chance findings due to increased type I error. Also, we could not consider potential differences 383 
in the content of carcinogens because we lacked information on tobacco brands, likely to contain varying 384 
amounts of heavy metals (42) and other carcinogens (39). Residual confounding can be therefore 385 
expected, also due to lack of, or imprecise, information on other relevant data such as ETS in adulthood. 386 
Extensive efforts have been made to adjust for as much confounding as possible, thereby alleviating the 387 
bias to the highest extent possible. Moreover, differential misclassification of the exposure due to recall 388 
bias of smoking habits among either the cases or controls is possible, or because use of only black or 389 
blond tobacco smoking might not have been reliably reported. Therefore, mixed effects due to alternate 390 
use of both tobacco types cannot be ruled out. We considered only smokers of black or blond tobacco in 391 
order to keep the effects by tobacco type separate, and considered switching from one type to the other in 392 
the group of users of both tobacco types.  393 
Major strengths of the study are the large number of PC cases representing a European-wide PC 394 
population and the degree of detail in the information collected about smoking habits. This allowed us to 395 
undertake exhaustive and solid analyses considering many aspects of the habit in relation to PC risk. In 396 
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fact, this is the first study assessing PC risk by black and blond tobacco. Also, as a novelty, the shapes of 397 
dose-response relationships have been fully characterized using different modelling strategies to account 398 
for non-linear effects of smoking on PC risk.  399 
In conclusion, findings of this study support and add to the previous evidence that smoking 400 
increases PC risk and demonstrates, for the first time, that both blond and black tobacco smoke are key in 401 
PC aetiology, though probably acting through different genetic mechanisms. Considering these smoking-402 
related PC risk profiles may help to refine the definition of high-risk PC population towards screening 403 
interventions implementation. Future studies should confirm our findings on type of tobacco and shed light 404 
on the mechanisms underlying their differential association with PC risk.  405 
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 520 
Table 1: Baseline characteristics of the PanGenEU study population (2,009 cases and 1,532 controls). 
  PanGenEU  PanGenEU - Spain 
  Cases (%) Controls (%) p-value2  Cases (%) Controls (%) p-value2 
Country      <0.001     -- 
  Spain 876 (43.6) 762 (49.7)  876 (100.0) 762 (100.0)  
  England 126 (6.3) 22 (1.4)  - - - -  
  Germany 130 (6.5) 111 (7.3)  - - - -  
  Ireland 173 (8.6) 290 (18.9)  - - - -  
  Italy 533 (26.5) 0 (0.0)  - - - -  
  Sweden 171 (8.5) 347 (22.7)  - - - -  
Gender      0.164     0.455 
  Female 871 (43.4) 701 (45.8)  384 (43.8) 349 (45.8)  
  Male 1138 (56.6) 831 (54.2)  492 (56.2) 413 (54.2)  
Age       <0.001     0.086 
 ≤54 413 (20.6) 262 (17.1)  157 (17.9) 155 (20.3)  
 55-64 497 (24.7) 321 (21.0)  203 (23.2) 173 (22.7)  
 65-74 699 (34.8) 495 (32.3)  285 (32.5) 208 (27.3)  
 ≥75 400 (19.9) 454 (29.6)  231 (26.4) 226 (29.7)  
BMI (kg/m2)      0.997     0.900 
  < 25 769 (38.3) 588 (38.4)  303 (34.6) 271 (35.6)  
  25-29.99 854 (42.5) 651 (42.5)  397 (45.3) 343 (45.0)  
  ≥ 30 386 (19.2) 293 (19.1)  176 (20.1) 148 (19.4)  
Alcohol status3     <0.001     0.412 
 Never-drinker 585 (29.1) 383 (25.0)  273 (31.2) 254 (33.3)  
 Light drinker  805 (40.1) 756 (49.3)  377 (43.0) 338 (44.4)  
 Moderate drinker 564 (28.1) 360 (23.5)  214 (24.4) 160 (21.0)  
 Heavy drinker 55 (2.7) 33 (2.2)  12 (1.4) 10 (1.3)  
Family history of PC    <0.001     <0.001 
 No 1882 (93.7) 1492 (97.4)  815 (93.00) 739 (97.0)  
 Yes 127 (6.3) 40 (2.6)  61 (7.0) 23 (3.0)  
Ever been diagnosed with asthma   <0.001     0.014 
 No 1878 (93.5) 1374 (89.7)  817 (93.3) 684 (89.8)  
 Yes 131 (6.5) 158 (10.3)  59 (6.7) 78 (10.2)  
Ever been diagnosed with diabetes   <0.001     <0.001 
  No 1515 (75.4) 1349 (88.1)  604 (68.9) 630 (82.7)  
 Yes, ≤ 2 years 214 (10.7) 27 (1.7)  112 (12.8) 20 (2.6)  
  Yes, >2 years 280 (13.9) 156 (10.2)  160 (18.3) 112 (14.7)  
Ever been diagnosed with chronic pancreatitis 0.004     0.460 
 No 1990 (99.1) 1530 (99.9)  871 (99.4) 760 (99.7)  
 Yes 19 (0.9) 2 (0.1)  5 (0.6) 2 (0.3)  
PC: pancreatic cancer; BMI: body mass index. 521 
Descriptives are shown for the imputed baseline characteristics. Descriptives of the unimputed baseline characteristics can be found in Supplementary Table 9 522 
1 Chi-square test applied to evaluate differences between the groups. Significance was set at p-value<0.05 523 
2 Light drinker: 0-1 drink/day for men and women; Moderate drinker: men: 1-5drinks/day, women: 1-2.5 drinks/day; Heavy drinker: men: ≥5drinks/day, women: 524 
≥2.5 drinks/day 525 
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ETS: environmental tobacco smoke 527 
Risk estimates are shown for the imputed smoking variables. Risk estimates of the unimputed smoking variables can be found in Supplementary Table 5 528 
Adjusted model for age (≤ 54, 55-64, 65-74, ≥75 years), gender (male, female) and country (Spain, England, Germany, Ireland, Italy, Sweden). Random effects 529 
model applied for country 530 
1 Chi-square test applied to evaluate differences between the groups. Significance was set at p-value<0.05 531 
 532 
Table 2: Association between smoking variables and pancreatic cancer risk in the PanGenEU study population (2,009 cases and 1,532 controls). 
     Unadjusted Adjusted 
  Cases (%) Controls (%) p-value1 OR (95%CI) aOR (95%CI) 
Smoking status (cigarettes) <0.001      
  Never-smoker 759 (37.8) 690 (45.0)  1.00  1.00  
  Occasional 33 (1.6) 42 (2.7)  0.72 (0.44 - 1.14) 1.00 (0.61 - 1.67) 
  Former 667 (33.2) 530 (34.6)  1.14 (0.98 - 1.33) 1.14 (0.95 - 1.37) 
  Current 550 (27.4) 270 (17.6)  1.85 (1.55 - 2.21) 1.72 (1.39 - 2.12) 
         p-trend <0.001 
Smoking intensity in tertiles (cigarettes per day) <0.001     
  Never-smoker 759 (37.8) 690 (45.0)  1.00  1.00  
  < 10 389 (19.4) 343 (22.5)  1.03 (0.86 - 1.23) 1.02 (0.83 - 1.25) 
 10 - 20 533 (26.5) 287 (18.7)  1.69 (1.42 - 2.02) 1.64 (1.34 - 2.02) 
 ≥ 20 328 (16.3) 212 (13.8)  1.41 (1.15 - 1.72) 1.41 (1.12 - 1.78) 
         p-trend <0.001 
Smoking duration in tertiles (years)  <0.001     
 Never-smoker 759 (37.8) 690 (45.0)  1.00  1.00  
 < 23 292 (14.5) 284 (18.5)  0.93 (0.77 - 1.13) 0.91 (0.72 - 1.14) 
 23 - 35 477 (23.8) 281 (18.4)  1.54 (1.29 - 1.85) 1.52 (1.23 - 1.87) 
 ≥ 35 481 (23.9) 277 (18.1)  1.58 (1.32 - 1.89) 1.51 (1.23 - 1.86) 
         p-trend <0.001 
Cumulative dose in tertiles (pack-years)  <0.001     
  Never-smoker 759 (37.8) 690 (45.0)  1.00  1.00  
  < 14 279 (13.9) 281 (18.3)  0.90 (0.74 - 1.10) 0.90 (0.72 - 1.13) 
 14 - 32 494 (24.6) 275 (18.0)  1.63 (1.36 - 1.96) 1.57 (1.27 - 1.94) 
  ≥ 32 477 (23.7) 286 (18.7)  1.52 (1.27 - 1.81) 1.50 (1.21 - 1.84) 
         p-trend <0.001 
Age at smoking initiation in tertiles (years)  <0.001     
 Never-smoker 759 (37.8) 690 (45.0)  1.00  1.00  
 < 15 423 (21.1) 278 (18.1)  1.38 (1.15 - 1.66) 1.36 (1.10 - 1.70) 
 15 - 18 455 (22.6) 299 (19.6)  1.38 (1.16 - 1.65) 1.31 (1.06 - 1.61) 
 ≥ 18  372 (18.5) 265 (17.3)  1.28 (1.06 - 1.54) 1.29 (1.04 - 1.59) 
         p-trend = 0.010 
Inhalation  <0.001     
 Never-smoker 759 (37.8) 690 (45.0)  1.00  1.00  
 Mouth only 125 (6.2) 99 (6.5)  1.15 (0.86 - 1.53) 1.10 (0.80 - 1.50) 
 Throat 158 (7.9) 108 (7.1)  1.33 (1.02 - 1.74) 1.48 (1.11 - 1.99) 
 Chest 967 (48.1) 635 (41.4)  1.38 (1.20 - 1.60) 1.33 (1.12 - 1.58) 
         p-trend <0.001 
Filter-use  <0.001     
  Never-smoker 759 (37.8) 690 (45.0)  1.00  1.00  
 Filtered only 1042 (51.9) 706 (46.1)  1.34 (1.17 - 1.54) 1.25 (1.06 - 1.48) 
 Non-filtered only 65 (3.2) 49 (3.2)  1.20 (0.82 - 1.78) 1.69 (1.10 - 2.61) 
  Both 143 (7.1) 87 (5.7)  1.49 (1.12 - 1.99) 1.65 (1.21 - 2.27) 
         p-trend <0.001 
ETS exposure during childhood  <0.001     
 Both parents were never-smokers 420 (20.9) 391 (25.6)  1.00  1.00  
 One of the parents smoked 1378 (68.6) 952 (62.1)  1.35 (1.15 - 1.58) 1.24 (1.03 - 1.49) 
 Both parents smoked 211 (10.5) 189 (12.3)  1.04 (0.82 - 1.32) 1.07 (0.81 - 1.42) 
         p-trend = 0.610 
Time since cessation in tertiles (years)  <0.001     
 Current smoker 551 (27.4) 274 (17.9)  1.00  1.00  
 < 14 320 (15.9) 191 (12.5)  0.83 (0.66 - 1.05) 0.81 (0.62 - 1.04) 
 14 - 28 229 (11.4) 185 (12.1)  0.62 (0.48 - 0.78) 0.67 (0.51 - 0.88) 
 ≥ 28 150 (7.5) 192 (12.5)  0.39 (0.30 - 0.50) 0.49 (0.36 - 0.66) 
 Never-smoker 759 (37.8) 690 (45.0)  - - - - 
         p-trend <0.001 
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Table 3: Association between smoking variables and pancreatic cancer risk by tobacco type and smoking status in the PanGenEU-
Spain study population (876 cases and 762 controls). 
     Unadjusted Adjusted  
  Cases (%) Controls (%) p-value1 OR (95%CI) aOR (95%CI)  
Tobacco type     0.012       
  Never-smoker 355 (40.5) 360 (47.2)  1.00  1.00   
  
Smoker of black 
tobacco only  165 (18.8) 114 (15.0) 
 
1.47 (1.11 - 1.94) 1.55 (1.13 - 2.12) 
 
  
Smoker of blond 
tobacco only  204 (23.3) 182 (23.9) 
 
1.14 (0.89 - 1.46) 1.23 (0.94 - 1.62) 
 
  
Smoker of both 
tobacco types 152 (17.4) 106 (13.9) 
 
1.45 (1.09 - 1.94) 1.58 (1.14 - 2.17) 
 
Tobacco type by smoking status  0.028      
 Never-smoker 369 (42.0) 377 (49. 5)  1.00  1.00   
 Former           
 Black tobacco 104 (11.9) 79 (10.4)  1.34 (0.97 - 1.87) 1.40 (0.98 - 1.99)  
 Blond tobacco 90 (10.3) 88 (11.5)  1.04 (0.75 - 1.45) 1.12 (0.79 - 1.57)  
 Both  76 (8.7) 58 (7.6)  1.34 (0.92 - 1.94) 1.44 (0.97 - 2.14)  
 Current           
 Black tobacco 60 (6.8) 31 (4.1)  1.98 (1.26 - 3.16) 2.09 (1.31 - 3.41)  
 Blond tobacco 103 (11.8) 83 (10.9)  1.27 (0.92 - 1.75) 1.43 (1.01 - 2.04)  
 Both  74 (8.5) 46 (6.0)  1.64 (1.11 - 2.45) 1.81 (1.19 - 2.76)  
Risk estimates are shown for the imputed smoking variables  535 
Adjusted model for age (≤ 54, 55-64, 65-74, ≥75 years), gender (male, female) and region (East, Central and Northern Spain) 536 
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Table 4: Combined effects of smoking duration and tobacco type on pancreatic cancer risk in the PanGenEU-Spain study population (876 
cases and 762 controls). 
 
Smoking duration of blond tobacco (years) 











































(0.65 - 1.64) 
42/47 
1.27 
(0.81 - 2.00) 
51/45 
1.33 




(0.71 - 2.64) 
25/17 
0.84 
(0.66 - 1.07) 
25/32 
0.93 
(0.52 - 1.67) 
10/8 
1.43 





(0.92 - 3.09) 
31/21 
1.28 
(0.38 - 4.28) 
7/2 
3.91 
(0.79 - 19.33) 
13/6 
2.61 





(1.11 - 2.27) 
109/76 
1.86 
(0.84 - 4.13) 
18/11 
1.83  
(0.79 - 4.26) 
15/10 
2.05  
(1.25 - 3.36) 
56/31 
Risk estimates are shown for the imputed smoking variables  555 
Adjusted OR for age (≤ 54, 55-64, 65-74, ≥75 years), gender (male, female) and region (East, Central and Northern Spain) 556 
Relative excess risk due to interaction = RERI=0.206, 95%CI: -0.49 - 0.91 557 
 558 
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Fractional polynomials aOR (95% CI) per 1-unit increase 
  Model 1 Model 2 Model 3 
 LR test1     
 p-value Formula resulting from the fractional polynomials
2 aOR (95%CI) aOR (95%CI) aOR (95%CI) 





  1.11 (1.04 - 1.20) 1.00 (0.89 - 1.11) 0.96 (0.87 - 1.07) 













))  1.07 (1.04 - 1.10) 1.05 (1.00 - 1.11) 0.99 (0.93 - 1.06) 













))    1.04 (1.02 - 1.05) 1.03 (1.02 - 1.05) N.A. 





  1.29 (1.18 - 1.45) N.A. 1.04 (0.88 - 1.23) 





  1.24 (1.16 - 1.35) N.A. N.A. 










  0.81 (0.74 - 0.88) 0.80 (0.72 - 0.87) 0.89 (0.71 - 1.05) 
Time since cessation (years)  











  0.85 (0.74 - 0.96) 0.85 (0.73 - 0.96) 0.88 (0.66 - 1.11) 
PC: pancreatic cancer; N.A.: not applicable 
Risk estimates are shown for the unimputed continuous smoking variables 
Model 1: adjusted for age (≤ 54, 55-64, 65-74, ≥75 years), gender (male, female) and country (Spain, England, Germany, Ireland, Italy, Sweden); 
Model 2: Model 1 plus additional adjustment for smoking intensity (cigarettes per day, continuous, non-linear);  
Model 3: Model 1 plus additional adjustment for smoking duration (years, continuous, non-linear) 
 
1 Likelihood ratio test (LR test) comparing two models, adjusted for age (≤ 54, 55-64, 65-74, ≥75 years), gender (male, female), and country (Spain, England, Germany, Ireland, Italy, Sweden), with and without restricted cubic splines 
applied (knots at 10, 50 and 90%)  
2 Fractional polynomials adjusted for age (≤ 54, 55-64, 65-74, ≥75 years), gender (male, female), and country (Spain, England, Germany, Ireland, Italy, Sweden) 
3 Never-smokers were removed from time since cessation variables  
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Figures 
 
Figure 1 (A-I): Dose-response relationships between several smoking variables and the risk of PC, 
depicted by restricted cubic splines with knots at 10%, 50% and 90%, represented as dashed, vertical 
lines. Adjusted for age, gender and country (for the PanGenEU study population), or region (for the 
PanGenEU-Spain study population). Restricted cubic splines are shown for the unimputed smoking 
variables, and additional adjustment variables were modelled as fractional plolynomials to account for 
non-linear effects. The spline curve is shown as a black trend line and 95% confidence intervals are 
shadowed in grey. The dotted horizontal black line represents the reference odds ratio of 1. A: Smoking 
duration in years (PanGenEU); B: Smoking duration in years (PanGenEU), adjusted for smoking 
intensity (cigarettes per day); C: Cumulative dose in pack-years (PanGenEU); D: Smoking intensity in 
cigarettes per day (PanGenEU); E: Smoking intensity in cigarettes per day (PanGenEU), adjusted for 
smoking duration (years); F: Time since cessation in years (PanGenEU), adjusted for cumulative dose 
(pack-years); G: Time since cessation in years (PanGenEU-Spain), adjusted for cumulative dose (pack-
years); H: Time since cessation in years for smokers of only black tobacco (PanGenEU-Spain), 
adjusted for cumulative dose (pack-years); I: Time since cessation in years for smokers of only blond 
tobacco (PanGenEU-Spain), adjusted for cumulative dose (pack-years). PC: pancreatic cancer; RCS: 
restricted cubic splines 
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